Atrial Fibrillation-A Puzzle for Treatment and New Approaches?

Dr. R. Aravazhi, MD, DnB, DM(Card)1*, Dr. M. Venkatesh, MD Gen Medicine2

1Assistant Professor of Cardiology, Govt. Theni Medical College, Opp Govt Theni Medical College, K. Villakku, Tamil Nadu, 625531, India
2Associate Professor, Govt. Theni Medical College, Opp Govt Theni Medical College, K. Villakku, Tamil Nadu, 625531, India

DOI: 10.36347/SJAMS.2019.v07i10.043 | Received: 23.09.2019 | Accepted: 01.10.2019 | Published: 30.10.2019

*Corresponding author: Dr. R. Aravazhi

Abstract

Atrial fibrillation is the commonest sustained cardiac arrhythmia. It accounts for >35% of all hospital admissions for cardiac arrhythmias. The presence of atrial fibrillation increases the mortality of a population by up to twofold. The risk of stroke increases from 1.5% in patients with atrial fibrillation from 50–59 years of age to up to 23.5% for such patients aged 80–89 years. Atrial fibrillation is the commonest cardiac arrhythmia. It affects 5% of people above the age of 65 years and 10% above 75. The most important morbidity and mortality associated with atrial fibrillation result from stroke. The attributable risk of stroke increased from 1.5% for patients with atrial fibrillation aged 50–59 years to 23.5% for those aged 80–89 years. It is also associated with congestive heart failure. Present study revealed 38 patients who were treated for AF with arrhythmic drugs and ablation were quite stable with atrial flutter as clinical problem and the remaining 24 patients showed recurrences even after combination of treatment.

Keywords: Drugs, electric cardioversion, ablation, pacemaker.

Copyright @ 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

PHYSIOLOGY

Atrial fibrillation is a heart rhythm disturbance that causes an irregular (and often rapid) heartbeat. It replaces the normal heartbeat, which originates in the sinus node (Figure-1) [1].

During atrial fibrillation, the top chambers of the heart (the atria) lose their normal, organized electrical activity and develop a chaotic, unorganized rhythm that makes the bottom chambers (the ventricles) beat irregularly (Figure-2) [1].

Fig-1

Fig-2
**INTRODUCTION**

Atrial fibrillation is the commonest sustained cardiac arrhythmia. It accounts for >35% of all hospital admissions for cardiac arrhythmias. The presence of atrial fibrillation increases the mortality of a population by up to twofold. The risk of stroke increases from 1.5% in patients with atrial fibrillation from 50–59 years of age to up to 23.5% for such patients aged 80–89 years. Atrial fibrillation is the commonest cardiac arrhythmia. It affects 5% of people above the age of 65 years and 10% above 75. The most important morbidity and mortality associated with atrial fibrillation result from stroke. The attributable risk of stroke increased from 1.5% for patients with atrial fibrillation aged 50–59 years to 23.5% for those aged 80–89 years. It is also associated with congestive heart failure [2].

**DEFINITION**

Atrial fibrillation is defined when there is complete absence of coordinated atrial systole resulting in the absence of P wave before each QRS complex in the electrocardiogram (ECG). The P waves are replaced by fibrillatory “f” waves which vary in size, shape, and timing [6] (caution: atrial fibrillation with complete heart block may present with regular R-R intervals in the ECG).

**CAUSES**

**Cardiovascular causes**
- Hypertension.

**Non-cardiovascular causes**
- Hyperthyroidism.
- Pneumonia/chronic obstructive airways disease.
- Alcohol binge.
- Postoperative (non-cardiac surgery).

**PRINCIPLE OF TREATMENT** [2]

The present treatment of atrial fibrillation is based on four main principles:
1. Restoration of sinus rhythm.
2. Rate control.
4. Prevention of thromboembolism

**MATERIAL AND METHODS**

62 patients suffering with atrial fibrillation were identified who have taken treatment earlier from registry were examined in the department of cardiology. These patients were treated with arrhythmic drugs, electrical cardioversion. However, new approaches such as preventative pacing, the atrial defibrillator and focal or linear catheter ablation have been developed for a subgroup of patients, depending on the mechanism of AF initiation or refractoriness to drug therapy. The concomitant use of drugs and pacing or ablation has recently been named ‘hybrid treatment’ [3].
DISCUSSION

Schumacher et al., [4] reported on a series of 187 patients from an AF registry who were treated with either oral flecainide or propafenone. Of these patients, 12.8% developed atrial flutter during follow-up. Electrophysiological study then revealed typical atrial flutter in 20 patients (10.7%). All patients underwent right atrial linear isthmus ablation.

These findings were supported by Nabar et al., [5] who studied the effect of additional isthmus ablation for atrial flutter in 24 consecutive patients presenting with AF who developed atrial flutter after intravenous administration of propafenone or flecainide.

In a larger study conducted in 82 consecutive patients, Nabar et al., [6] studied patients with documented typical atrial flutter with or without concomitant AF. In their series, linear isthmus ablation was performed in all patients.

In a report by Huang and coworkers [7] on 13 patients who converted to either typical or atypical atrial flutter following antiarrhythmic drug treatment, a total of 88.9% of the patients remained in sinus rhythm after successful ablation of the inferior isthmus.

In another very interesting report, Philippon et al., [8] studied the risk for recurrence of AF in patients who had atrial flutter as the major clinical problem and AF as a concomitant arrhythmia. In their series of patients, after isthmus ablation of atrial flutter, they observed a recurrence of atrial flutter in 5.9% of the patients and recurrence of AF in 26.4%.

Present study revealed 38 patients who were treated for AF with arrhythmic drugs and ablation were quite stable with atrial flutter as clinical problem and the remaining 24 patients showed recurrences even after combination of treatment.

CONCLUSION

Because antibradycardia pacing and ablation have not proven to be sufficiently effective when used as a stand-alone therapy in the prevention of AF on a larger scale, combined therapy using these non-pharmacological approaches and antiarrhythmic drugs may be the approach of choice for many patients. One possible way to achieve clinical and symptomatic improvement in a subgroup of patients with AF is a hybrid therapy with a class IC drug and linear isthmus ablation. There is no single and definitive treatment for atrial fibrillation.

REFERENCES
4. Schumacher B, Jung W, Lewalter T, Vahlhaus C, Wolpert C, Lüderitz B. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. The


